A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

• Drug: 3 mg PF-06412562 MR tablets_Fasted
  
  A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
• Drug: 2 x 15 mg PF-06412562 MR tablets_Fasted
  
  Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
• Drug: 2 x 15 mg PF-06412562 MR tablets_Fed
  
  Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
• Drug: 10 mg PF-06412562 IR tablets
  
  a single immediate release tablet of 10 mg PF-06412562 after an overnight fast

• Experimental: Arm 1
  
  Intervention: Drug: 3 mg PF-06412562 MR tablets_Fasted
• Experimental: 2
  
  Intervention: Drug: 2 x 15 mg PF-06412562 MR tablets_Fasted
• Experimental: 3
  
  Intervention: Drug: 2 x 15 mg PF-06412562 MR tablets_Fed
• Experimental: 4
  
  Intervention: Drug: 10 mg PF-06412562 IR tablets

Inclusion Criteria:

• Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs);

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• A positive urine drug screen.
• Subjects who have attempted suicide in the past.
• Subjects who have an unexplained history of sudden death in their family